Symbols

Teva Stock Surges: Keytruda Biosimilar Deal Drives Growth

Friday, Jun 6, 2025 5:34 am ET1min read

Teva Pharmaceutical Industries Limited rose 1.04% in premarket trading. The company's stock price increase may be attributed to the recent collaboration between AlvotechALVO-- and Dr. Reddy's to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. This collaboration could potentially lead to significant revenue growth for TevaTEVA--, as Keytruda® had worldwide sales of US$29.5 billion in 2024.

StockSavvy

Insightful stock picks for the savvy investor.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue